MCID: CHR043
MIFTS: 16

Chronic Inflammatory Demyelinating Polyneuritis

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuritis:

Name: Chronic Inflammatory Demyelinating Polyneuritis 12 15
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2536
ICD10 33 G61.81
ICD9CM 35 357.81
MeSH 44 D020277
NCIt 50 C84636
UMLS 73 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyneuritis

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuritis, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to chronic inflammatory demyelinating polyradiculoneuropathy and chronic inflammatory demyelinating polyneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuritis is FASLG (Fas Ligand). The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder.

Related Diseases for Chronic Inflammatory Demyelinating Polyneuritis

Diseases related to Chronic Inflammatory Demyelinating Polyneuritis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyradiculoneuropathy 12.1
2 chronic inflammatory demyelinating polyneuropathy 12.0
3 polyradiculoneuropathy 10.8

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuritis

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuritis

Drugs for Chronic Inflammatory Demyelinating Polyneuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Not Applicable
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9 tannic acid Approved Phase 3
10
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
11
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
12 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
13 Fingolimod Hydrochloride Phase 3
14 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
15 Hormone Antagonists Phase 3,Phase 1,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
17 glucocorticoids Phase 3,Phase 1,Phase 2
18 Hormones Phase 3,Phase 1,Phase 2
19 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
20 Pharmaceutical Solutions Phase 3,Phase 2
21
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
22
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
23
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
24
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
25
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
26
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
27
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
28
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
29
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
32 Antioxidants Phase 2
33 Vitamin B9 Phase 2
34 Vitamins Phase 2
35 Protective Agents Phase 2,Phase 1
36 Thioctic Acid Phase 2
37 Trace Elements Phase 2
38 Alpha-lipoic Acid Phase 2
39 Folate Phase 2
40 Vitamin B Complex Phase 2
41 Micronutrients Phase 2
42 Interferon-beta Phase 2
43 Antiviral Agents Phase 2
44 Anti-Infective Agents Phase 2
45 Adjuvants, Immunologic Phase 2,Phase 1
46 interferons Phase 2
47 Antirheumatic Agents Phase 1, Phase 2,Phase 2
48 Gastrointestinal Agents Phase 1, Phase 2
49 Methylprednisolone acetate Phase 1, Phase 2
50 Krestin Phase 1, Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
7 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
10 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
11 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
12 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
13 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
16 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
17 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
18 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
19 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
20 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
21 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
22 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
23 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
24 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
25 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
26 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
27 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
28 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
29 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
30 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
31 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
32 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
33 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
34 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
35 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
36 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
37 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
38 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
39 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
40 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
41 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
42 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
43 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022 Not Applicable
44 Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Recruiting NCT03656640 Gammanorm
45 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
46 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
47 Transcriptome Analysis of the Peripheral Blood in CIDP Active, not recruiting NCT02404298 Not Applicable IVIg
48 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Not Applicable Standard of Care
49 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890 Not Applicable
50 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: polyradiculoneuropathy, chronic inflammatory demyelinating

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuritis

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuritis

Publications for Chronic Inflammatory Demyelinating Polyneuritis

Variations for Chronic Inflammatory Demyelinating Polyneuritis

Expression for Chronic Inflammatory Demyelinating Polyneuritis

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuritis.

Pathways for Chronic Inflammatory Demyelinating Polyneuritis

GO Terms for Chronic Inflammatory Demyelinating Polyneuritis

Biological processes related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 8.62 FASLG KNG1

Molecular functions related to Chronic Inflammatory Demyelinating Polyneuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.62 FASLG KNG1

Sources for Chronic Inflammatory Demyelinating Polyneuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....